GlassScriptPhysician profile
Donald M Micallef
NPI 1467486365
$4,666.33
in general payments reported to CMS, 2019-2025
29 companies · $538 in 2025
The $538 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $923 · 2020: $347 · 2021: $1,036 · 2022: $648 · 2023: $482 · 2024: $692 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,712.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $666.81 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $635.89 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.38 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $369.47 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $368.43 | 2021-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $362.73 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $271.84 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $249.78 | 2019-2021 | |
| Glaxosmithkline, LLC. | $174.24 | 2020-2022 | |
| Astellas Pharma US INC | $162.28 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $150.30 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $137.74 | 2019-2021 | |
| Abbvie INC. | $128.10 | 2021-2025 | |
| Amarin Pharma, INC. | $81.70 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $69.50 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $69.10 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.69 | 2019-2021 | |
| Lundbeck LLC | $52.58 | 2024-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $43.67 | 2022-2024 | |
| Dexcom, INC. | $35.44 | 2024-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $26.27 | 2019 | |
| Esperion Therapeutics, INC. | $16.99 | 2024 | Nexletol |
| Hikma Pharmaceuticals USA | $14.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.88 | 2021 | |
| Genentech USA, INC. | $14.53 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.52 | 2022 | |
| Bausch Health US, LLC | $13.26 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.67 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Micallef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.